131 related articles for article (PubMed ID: 38562257)
1. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Zheng Z; Lin Y; Cai H
Front Public Health; 2024; 12():1356244. PubMed ID: 38562257
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
6. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
[TBL] [Abstract][Full Text] [Related]
8. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
Zheng Z; Chen H; Cai H; Zhu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985
[TBL] [Abstract][Full Text] [Related]
9. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Shu Y; Tang Y; Ding Y; Zhang Q
Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
Lang W; Deng L; Huang B; Zhong D; Zhang G; Lu M; Ouyang M
Clin Drug Investig; 2024 Mar; 44(3):149-162. PubMed ID: 38300386
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
17. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
Meng R; Cao Y; Zhou T; Hu H; Qiu Y
Front Public Health; 2022; 10():794131. PubMed ID: 35433574
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]